Shares in pharmaceutical company GlaxoSmithKline (GSK) surged more than 6% after ... This was due to increasing fears that its main active ingredient, ranitidine, could potentially turn into a ...
GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...
In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...